期刊
INTERNATIONAL JOURNAL OF STROKE
卷 7, 期 5, 页码 386-397出版社
SAGE PUBLICATIONS LTD
DOI: 10.1111/j.1747-4949.2012.00802.x
关键词
acute stroke; animal models; diabetes; hypertension; risk factors; stroke therapies
资金
- Medical Research Council [G0501797]
- NHMRC Program, Fellowship and Project Grants
- MRC [G0501797] Funding Source: UKRI
- Medical Research Council [G0501797] Funding Source: researchfish
The main driving force behind the assessment of novel pharmacological agents in animal models of stroke is to deliver new drugs to treat the human disease rather than to increase knowledge of stroke pathophysiology. There are numerous animal models of the ischaemic process and it appears that the same processes operate in humans. Yet, despite these similarities, the drugs that appear effective in animal models have not worked in clinical trials. To date, tissue plasminogen activator is the only drug that has been successfully used at the bedside in hyperacute stroke management. Several reasons have been put forth to explain this, but the failure to consider comorbidities and risk factors common in older people is an important one. In this article, we review the impact of the risk factors most studied in animal models of acute stroke and highlight the parallels with human stroke, and, where possible, their influence on evaluation of therapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据